Revolution Medicines gets FDA approval for targeted pancreatic cancer drug

https://images.jpost.com/image/upload/f_auto,fl_lossy/q_auto/c_fill,g_faces:center,h_3675,w_5512/735310" title="Menta "Steve" Wallace shows a bottle of daraxonrasib, Revolution Medicine?s pancreatic cancer drug, at his home in The Woodlands, Texas, U.S., May 29, 2026. (photo credit: REUTERS/Danielle Villasana)" />
The drug, branded as Rasonque and also known as daraxonrasib, is a once-daily pill designed to block several forms of the RAS protein, which helps drive tumor growth in many pancreatic cancers.